ARCA BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.58 USD | +2.87% |
|
+5.29% | +110.59% |
| 25/04 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 19/04 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 24.5M 2.04B |
|---|---|---|---|---|---|
| Net income 2022 | -9M -751M | Net income 2023 | -5M -417M | EV / Sales 2022 | - |
| Net cash position 2022 | 42.06M 3.51B | Net cash position 2023 | 37.15M 3.1B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-3.44
x | P/E ratio 2023 |
-4.59
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.71% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.87% | ||
| 1 week | +5.29% | ||
| Current month | +103.41% | ||
| 1 month | +103.41% | ||
| 3 months | +112.46% | ||
| 6 months | +91.44% | ||
| Current year | +110.59% |
1 week
3.41
3.75
1 month
1.693.88
Current year
1.563.88
1 year
1.563.88
3 years
1.563.90
5 years
1.5622.00
10 years
1.56207.90
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Keuer
CEO | Chief Executive Officer | 65 | 01/06/01 |
C. Dekker
DFI | Director of Finance/CFO | 60 | 10/21/10 |
Sharon Perry
LAW | General Counsel | - | 01/08/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anders Hove
BRD | Director/Board Member | 58 | 16/17/16 |
Robert Conway
CHM | Chairman | 70 | 03/13/03 |
Linda Grais
BRD | Director/Board Member | 68 | 01/07/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.58 | +2.87% | 85,337 |
| 25/24/25 | 3.48 | -4.13% | 54,151 |
| 24/24/24 | 3.63 | -0.55% | 97,762 |
| 23/24/23 | 3.65 | +5.80% | 211,848 |
| 22/24/22 | 3.45 | +1.47% | 294,997 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +110.59% | 51.91M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABIO Stock
